Advertisement
"I am pleased to welcome both Robert and Jeff to Novalar. Their experienceand successful track records will be indispensable as Novalar establishes thecommercial infrastructure required for the anticipated launch of NV-101, adental pharmaceutical currently under review by the FDA," stated Donna Janson,President and Chief Executive Officer of Novalar. "Their blend of dental andfinancial expertise, business acumen and entrepreneurial spirit reflects theevolution of our senior management team as we expand to support our futuregrowth," added Janson.
Advertisement
Robert Stefanovich brings over 15 years of experience in finance andoperations of both public and private companies in the high-tech and biotechsectors. Most recently, Mr. Stefanovich served as interim Chief FinancialOfficer of Xcorporeal, Inc., a publicly traded medical device company.Previously, Mr. Stefanovich served as Executive Vice President and ChiefFinancial Officer of Artemis International Solutions Corporation, apublicly-traded software company. He also held several other senior financepositions, including Chief Financial Officer of Aethlon Medical Inc. and VicePresident of Administration at SAIC, a Fortune 500 company. Mr. Stefanovichwas a member of the Software Advisory Group and Audit Manager withPricewaterhouseCoopers' high-tech practice in San Jose, CA and Frankfurt,Germany. He currently serves as a board member of Project InVisionInternational, a leading provider of business performance improvementsolutions. He received his Masters of Business Administration and Engineeringdegree from the University of Darmstadt, Germany.
Jeffrey Lord brings over 14 years of national sales experience indentistry, both direct and through distributors, with a track record ofsuccess in building and leading sales teams, launching products, developingmarkets and achieving sales goals. Most recently, Mr. Lord served as Area VicePresident at Straumann USA, a global leader in implant, restorative andregenerative dentistry. Previously, Mr. Lord served as Regional Sales Managerfor the Professional Division of Dentsply International, the largestprofessional dental company in the world. He also held senior sales positions,including Regional Sales Manager and Territory Manager at BIORA, Inc., whichdeveloped, manufactured, marketed and sold biology-based products for thetreatment of periodontal disease for use in oral surgery. Mr. Lord receivedhis BA in Sociology from the University of Washington in Seattle.
About NV-101
If approved by the FDA, NV-101 will be the only local dental anestheticreversal agent that accelerates the return to normal sensation and functionfollowing restorative and periodontal maintenance procedures. The product hasbeen tested in pediatric, adolescent and adult patients. Phentolamine mesylate(a vasodilator), the active ingredient in the investigational agent NV-101,has been approved and in use in specific medical indications at significantlyhigher doses for over 50 years.
About Novalar Pharmaceuticals, Inc.
San Diego-based Novalar Pharmaceuticals, Inc. is a privately heldspecialty pharmaceutical company focused on developing and commercializingnovel pharmaceuticals for the dental market. The company's initial productoffering, NV-101, is being developed for the reversal of soft tissueanesthesia and the associated functional deficits associated with local dentalanesthesia. For more information, visit http://www.novalarpharm.com.
SOURCE Novalar Pharmaceuticals, Inc.
